Artemis 2

Products	Artemis 2
Company	UltraLink LLC
Item	Artemis 2
Features	Extreme accuracy in corneal pachymetry. Ability to measure corneal flaps in 3D with 1-m precision. Ability to measure residual stromal beds in 3D for safe planning of enhancement LASIK surgery. Ability to accurately diagnose the sub-surface cause of complications of corneal refractive surgery. Unparalleled accuracy in single-sweep 3D angle-to-angle or sulcus-to-sulcus measurements. High-resolution B-scan imaging of the anterior or posterior chamber. Anatomical post-operative monitoring of IOL position. Diagnostics for complications post-IOL surgery.
Description	Artemis is the world's first very high frequency digital ultrasound eye arc-scanner. Using patented 3D Arc-scanning technology, Artemis provides microscopic resolution images and precision measurement capabilities of the cornea and anterior segments of the human eye. Artemis is a very high frequency (VHF) ultrasound eye scanner. In use, the patient leans forward placing their head onto an adjustable headrest. The headrest's unique design permits the patient to pull away quickly from the scanner if desired. An eyecup filled with a saline-based interface fluid couples the ultrasound signal to the eye, while a precision mechanism moves the transducer past the front of the eye. During the accurately controlled arc motion of the transducer, which lasts less than one second, many thousands of ultrasound samples are digitized. Following a scan, signal analysis is performed on a PC-compatible microcomputer, and the data are available for immediate viewing on an LCD monitor or archival storage to disc media.
Info	UltraLink LLC Customer Service: (727) 527-1277 Web site: http://www.arcscan.com

TAG: Artemis

...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...

Medicine Products:

Toxoplasma gondiiAntibodies, IgG & IgM Toxic-Shock Syndrome Panel Total Protein, CSF Total Complement CH100

(Date:9/5/2008)...On Saturday, September 6, PARI,Respiratory Equipme...ay,s,Family as part of their "Breathe Easier" seri...e company that provides patients, such as COPD,suf...that deliver needed,medications directly to the lu...e affected by respiratory,diseases and those who c...

(Date:9/5/2008)...disease resistance to anti-hormonal therapy , ...ug sorafenib may help "re-sensitize" certain breas...n University Medical Center researchers say. , ...tor positive (ER or PR positive) metastatic breast...as aromatase inhibitors, to keep the cancer under ...

(Date:9/4/2008)...-- A groundbreaking program,dealing with the deter...men, their shorter life spans, unmet gender specif... Wednesday, September 17 at White Plains,Hospital....Westchester,medical and psychiatric societies will...nel Tiger, Ph.D., Dr. Legatto, an internationally...

(Date:9/4/2008)... say could help doctors evaluate risks , ...afety experts say that almost all kids who are all...ose monitoring and a set of standard precautions. ...ics , a team of experts led by the Johns Hopkins C...nstructions -- an algorithm -- to help physicians ...

Breaking Medicine News(10 mins):Health News:PARI Respiratory Equipment Featured on Oxygen Network 2 Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2 Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2

[0] PARI Respiratory Equipment Featured on Oxygen Network [0] Drug Re-Sensitizes Breast Tumors to Treatment [0] The Decline of Males, Why They Die First; at White Plains Hospital September 17 [0] Even Kids With Known Allergies Can Be Safely Vaccinated

...t smaller amount of teenagers are drinking on a re...coming harder for youngsters to get hold of alcoh...2% in 2005 to 17% in the latest research. Those wh...k - cut down from 50% to 44%. On the other hand a ...

... reports have confirmed that she was drunk and had...ash in Beverly Hills on Memorial Day weekend. Ac...eports say that the Mean Girls star had cocaine an...alcohol in her system when she was arrested last m...

...nderstand the mechanism by which cells grow and ca...athogen Listeria Monocytogenes in their project. ...ntral Florida Microbiology Professor Keith Ireton,...protein called InlB induces internalisation and de...

...der in Andhra Pradesh, Thursday announced that it ...r to set up new state-of-the-art hospitals in six ...leted 10 years, plans to open new hospitals in Mad...a, Chhattisgarh, Gujarat, Orissa and Kerala. The ...

Other Medicine News:Health News:New Study That Small Amount of Teenagers Drinks on a Regular Basis 2 Health News:Study of Bacterial Pathogen may Give Insight to Cancer Development 2

New Study That Small Amount of Teenagers Drinks on a Regular Basis Lindsays Toxicology Reports Confirm Drug Use During Car Crash Study of Bacterial Pathogen may Give Insight to Cancer Development Leading Hospital in Andhra Plans Expansion

(Date:9/6/2008)...acy of First-in-Class Neurally Acting Anti-Migr...aine, LONDON, Sept. 6 /- CoLucid Pha...mpany focusing on therapies for central nervous,sy...lead compound COL-144,in the treatment of acute mi... and effective in relieving migraine headaches. CO...

(Date:9/5/2008)...FirstCall/ -- CEL-SCI Corporation,(Amex: CVM ) an...hritis data,at the Marcus Evans conference on Immu.... Daniel Zimmerman, Senior Vice President of Resea... CEL-SCI,s rheumatoid,arthritis vaccine CEL-2000 p...sed by rheumatoid arthritis in an animal model of ...

(Date:9/4/2008)...Newswire/ -- Cytopia Limited (ASX:,CYT) today anno...e Ib/II,study of CYT997, the company,s novel vascu...an aggressive form of brain cancer known as gliobl...is the first Phase II efficacy study in highly,vas... the second in its,suite of Phase II studies desig...

(Date:9/4/2008)..., and Presented at ESC Congress-, PHILADELPHIA, S...ional,study, the GISSI Heart Failure (GISSI-HF) st...esters reduced all cause mortality and hospital,ad...th chronic heart,failure. These findings are publi... and were presented at the European Cardiovascular...

Breaking Medicine Technology:Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008 2 Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2 Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3 Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4 Cytopia Commences Second Phase II Study in Brain Cancer 2 Cytopia Commences Second Phase II Study in Brain Cancer 3 New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2 New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3 New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4 Internal Medicine 2008 media advisory 17936 1 Internal Medicine 2008 media advisory 17936 2 Immune system kick started in moist nasal lining in sinusitis asthma and colds 17934 1 Immune system kick started in moist nasal lining in sinusitis asthma and colds 17934 2 Immune system kick started in moist nasal lining in sinusitis asthma and colds 17934 3 Scientists aim to boost world energy supplies with microbes 21 3101 1 Scientists aim to boost world energy supplies with microbes 21 3101 2 Scientists aim to boost world energy supplies with microbes 21 3101 3 Scientists aim to boost world energy supplies with microbes 21 3101 4 Scientists determine drug target for the most potent botulinum neurotoxin 3099 1 Scientists determine drug target for the most potent botulinum neurotoxin 3099 2

[0] Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008 [0] Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis [0] Cytopia Commences Second Phase II Study in Brain Cancer [0] New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients

... Evaluable Patients Receiving Combination of,Bavit...,Tumor Response or Stable Disease - , - 75% of ... Gemcitabine , ,Achieved Objective Tumor...Patients Receiving Combination of Bavituximab Plus...ive Tumor Response - , - Trial Results Suppo...

... (Asasantin® Retard) considered by many as,fir...IM, Germany, 31 May 2007 - New data presented toda...w confirm that therapy,with dipyridamole plus ASA ...d as Aggrenox® or Asasantin® Retard) is su...ents in patients who had,a TIA or minor ischaemic ...

Other Medicine Technology:Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 2 Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 3 Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 4 Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 5 New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 2 New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 3 New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 4

Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients